US 11,858,983 B2
C-terminal anti-sclerostin antibody variants
Zhe Huang, Action, MA (US); Jennitte LeAnn Stevens, Thousand Oaks, CA (US); Greg Flynn, Thousand Oaks, CA (US); Szilan Fodor, Thousand Oaks, CA (US); and Mark Daris, Thousand Oaks, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Sep. 23, 2022, as Appl. No. 17/934,585.
Application 17/934,585 is a continuation of application No. 16/971,590, granted, now 11,466,079, previously published as PCT/US2019/024739, filed on Mar. 29, 2019.
Claims priority of provisional application 62/812,741, filed on Mar. 1, 2019.
Claims priority of provisional application 62/650,762, filed on Mar. 30, 2018.
Prior Publication US 2023/0015713 A1, Jan. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/22 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/22 (2013.01) [A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01)] 24 Claims
 
1. An antibody that specifically binds to sclerostin of SEQ ID NO: 1 and comprises a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 9 and a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 10, wherein the antibody comprises two heavy chains, wherein at least one of the heavy chains comprises the amino acid sequence Pro-Ala-Arg-Gly (SEQ ID NO: 8) at the C-terminus of the heavy chain, wherein the C-terminus of one or both of the heavy chains is amidated.